NCT01289431

Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis

Dose Ranging Study to Evaluate the Safety and Efficacy of Mapracorat Ophthalmic Formulation, in Subjects With Allergic Conjunctivitis Compared to Vehicle in a Conjunctival Allergen Challenge (CAC).

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 236 (actual)
• Sponsor: Bausch & Lomb Incorporated · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to evaluate the dose response, and efficacy of Mapracorat ophthalmic formulation compared to its vehicle for the prevention of symptoms and signs associated with allergic conjunctivitis using a conjunctival allergen challenge (CAC) model.

Conditions

• Conjunctivitis, Allergic

Interventions

Type	Name	Description
DRUG	Mapracorat	administered daily to each eye for 2 weeks following allergen challenge using a CAC model
DRUG	Vehicle	administered daily to each eye for 2 weeks following allergen challenge using a CAC model

Timeline

• Start date: 2011-02-01
• Primary completion: 2011-04-01
• Completion: 2011-04-01
• First posted: 2011-02-03
• Last updated: 2020-09-04
• Results posted: 2020-09-04

Locations

1 site across 1 country: United States